Staphylococcus aureus News and Research

RSS

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.

Durata Therapeutics acquires Vicuron Pharmaceuticals

Durata Therapeutics, Inc. announced today that it has acquired Vicuron Pharmaceuticals from Pfizer (PFE). Durata is a newly formed biopharmaceutical company that was created by a five-member venture capital syndicate to pursue late-stage clinical development of novel antibiotic programs. The acquisition was funded through a stock purchase by New Leaf Venture Partners, LLC, Domain Associates, LLC, Aisling Capital, Sofinnova Ventures Inc. and Canaan Partners.

21 Dec 2009

Malaria nasal vaccine, antimicrobial peptide against MRSA, and safer method to prolong orange juice shelf life

An experiemental nasally administered malaria vaccine prevented parasite transmission from infected mice to mosquitoes and could play an important role in the fight against human malaria. The researchers from Japan report their findings in the December 2009 issue of the journal Infection and Immunity.

19 Dec 2009

PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study

PolyMedix, Inc., an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has successfully completed the first two segments of a Phase 1B clinical safety study with its novel antibiotic drug candidate PMX-30063.

18 Dec 2009

New licensing agreement to develop and commercialize prophylactic vaccine against MRSA signed

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that it has entered into an exclusive, world-wide licensing agreement with Syntiron to develop and commercialize its prophylactic vaccine against Staphylococcus, including Methicillin-Resistant Staphylococcus aureus or MRSA.

17 Dec 2009

Syntiron grants sanofi pasteur exclusive world-wide license to its human vaccine against MRSA

Syntiron today announced that it has granted sanofi pasteur an exclusive world-wide license to its human vaccine against Staphylococcus aureus. The agreement includes an undisclosed initial licensing fee, milestone payments and royalty payments on future sales of the product. Staphylococcus aureus, or MRSA (pronounced Mer-sa) is an important hospital-acquired infection and is a major cause of illness and death resulting in excess of 18,000 US deaths a year and a half million hospitalizations, creating a significant economic burden of approximately $3.4 billion annually to the American health care system.

16 Dec 2009

Pomegranate rind, metal salts and Vitamin C: An effective combination for treating MRSA infection

Pomegranates have already been hailed as a super-food but a team of scientists from Kingston University in South West London has found a new use for the deep red fruit. The team, led by Professor Declan Naughton, has discovered that the rind can be turned into an ointment for treating MRSA and other common hospital infections.

16 Dec 2009

MRSA, the most concerning pathogen to surveyed for skin and skin structure infections

Arlington Medical Resources (AMR) and Decision Resources find that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed European infectious disease specialists with regard to their treatment of skin and skin structure infections.

16 Dec 2009

Post-surgical infections raise healthcare expenditures

Post-surgical infections significantly increase the chance of hospital readmission and death and cost as much as $60,000 per patient, according to Duke University Medical Center researchers who conducted the largest study of its kind to date.

16 Dec 2009

Rib-X Pharmaceuticals and MGH enter into collaborative research agreement

Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of serious multi-drug-resistant infections announced today it has entered into a collaborative research agreement with Massachusetts General Hospital (MGH).

16 Dec 2009

Optiquant BKV Quantification Panel for MSSA DNA testing procedures

AcroMetrix, a leading provider of quality control standards for clinical diagnostic laboratories, announced today the launch of the first standardized quality control for MSSA molecular testing.

15 Dec 2009

FDA clears AdvanDx' 90 minutes PNA FISH protocol for S. aureus and CNS tests

AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its S. aureus PNA FISH® and S. aureus/CNS PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.

10 Dec 2009

Vestagen Technical Textiles introduces Nanotechnology-Based Healthcare Specialty Textiles

Vestagen Technical Textiles today announced its entry into the advanced performance textile arena with the introduction of the first of a new class of Nanotechnology-Based Healthcare Specialty Textiles.

9 Dec 2009

MicroPhage obtains CE mark to market MRSA/MSSA Blood Culture Test in Europe

MicroPhage announced today that it has obtained its CE Mark to market in Europe the first of its instrument-free, rapid tests based on its patented Bacteriophage Amplification technology.

8 Dec 2009

Guidelines to diagnose and manage complicated skin and soft tissue infections published

New evidence-based recommendations developed by the Surgical Infection Society to guide physicians in the diagnosis and management of complicated skin and soft tissue infections have been published in Surgical Infections, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com).

3 Dec 2009

Roche's MagNA Pure 96 System for nucleic acid purification evaluated

TriCore Reference Laboratories of Albuquerque, N.M., reported at a recent user meeting results of their research collaboration with Roche Applied Science in which they evaluated Roche´s new MagNA Pure 96 System for use in nucleic acid purification. The evaluation focused on the Roche system’s ability to process specimens for pathogen testing.

1 Dec 2009

Low-temperature plasma prototype devices as bactericidal cocktails

MRSA (methicillin-resistant Staphylococcus Aureus) and other drug-resistant bacteria could face annihilation as low-temperature plasma prototype devices have been developed to offer safe, quick, easy and unfailing bactericidal cocktails.

26 Nov 2009

MRSA making its way into hospitals, says study

The community-associated strain of the deadly superbug MRSA-an infection-causing bacteria resistant to most common antibiotics-poses a far greater health threat than previously known and is making its way into hospitals, according to a study in the December issue of Emerging Infectious Diseases.

24 Nov 2009

BD acquires HandyLab for $275 million

BD today announced the completion of its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms.

From BD (Becton, Dickinson and Company) 20 Nov 2009

Expansion of Excelyte manufacturing plant completed at Midland

Integrated Environmental Technologies, Ltd. announces that Benchmark Performance Group, Inc., its exclusive worldwide distributor serving the oil and gas industry, has completed the expansion of its Excelyte® manufacturing plant at its Midland, Texas facility.

19 Nov 2009

Recent developments at Burnham Institute for Medical Research

New antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) and other pesky bacteria. Andrei Osterman and collaborators have used comparisons of bacterial genomes to identify new targets for antibiotics and produced first-generation chemical inhibitors of a class of bacterial enzymes, called NadDs (nicotinate mononucleotide adenylyltransferases).

17 Nov 2009

Staphylococcus aureus News and Research

Further Reading

Durata Therapeutics acquires Vicuron Pharmaceuticals

Malaria nasal vaccine, antimicrobial peptide against MRSA, and safer method to prolong orange juice shelf life

PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study

New licensing agreement to develop and commercialize prophylactic vaccine against MRSA signed

Syntiron grants sanofi pasteur exclusive world-wide license to its human vaccine against MRSA

Pomegranate rind, metal salts and Vitamin C: An effective combination for treating MRSA infection

MRSA, the most concerning pathogen to surveyed for skin and skin structure infections

Post-surgical infections raise healthcare expenditures

Rib-X Pharmaceuticals and MGH enter into collaborative research agreement

Optiquant BKV Quantification Panel for MSSA DNA testing procedures

FDA clears AdvanDx' 90 minutes PNA FISH protocol for S. aureus and CNS tests

Vestagen Technical Textiles introduces Nanotechnology-Based Healthcare Specialty Textiles

MicroPhage obtains CE mark to market MRSA/MSSA Blood Culture Test in Europe

Guidelines to diagnose and manage complicated skin and soft tissue infections published

Roche's MagNA Pure 96 System for nucleic acid purification evaluated

Low-temperature plasma prototype devices as bactericidal cocktails

MRSA making its way into hospitals, says study

BD acquires HandyLab for $275 million

Expansion of Excelyte manufacturing plant completed at Midland

Recent developments at Burnham Institute for Medical Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News